Note: Ingredients listed on restricted chemical lists
EC/CAS
201-069-1/77-92-9
Name of the chemical
Citric acid
Concentration
*
EC/CAS
231-791-2/7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
*
General Information
Version
1.0
Revision date
2009-09-04
Product name
Metronidazole Injection
Product name
Metronidazole Injection
Identification on the label/Trade name
Not applicable
Chemical name
Mixture
1.2.1 Relevant identified uses
Pharmaceutical product used as antiprotozoal agent
Emergency telephone
1-800-424-9300, +44 (0)208 762 8322
Icons in SDS
Company Information
company name
Pfizer Inc
e-mail address of the competent person responsible for the Safety Data Sheet
pfizer-MSDS@pfizer.com
Hazard Codes
Hazard statements (CLP)
H351
Hazard statements
Code
Statements
H351
Suspected of causing cancer
Section 2
SECTION 2: Hazards identification
Appearance Liquid
Hazard statements
Non-hazardous in accordance with international standards for workplace safety.
Additional information
Short Term Ingestion of large amounts may cause central nervous system effects. Long Term Animal studies have shown a potential to cause adverse effects on the fetus. Suspected of causing cancer. Known Clinical Effects Clinical use of this drug has caused peripheral neuropathy, associated with numbness and tingling of the extremities, pain, and motor weakness. Effects on blood and blood-forming organs have also occurred. EU Indication of danger Not classified Note This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
